Figure 6
Human tumor growth inhibition in SCID mice treated with CTLs. A. Four groups of SCID mice (5 mice/group) were used. Group I (●) received LT391-06 tumor cells only (s.c. injection of 5 × 105 cells); Group II (○) received tumor cells and 1 × 106 influenza specific CTLs (nucleoprotein specific, HLA-B27 restricted); Group III (□) received 5 × 105 tumor cells and 5 × 105 tumor specific anti-LT391-06 CTLs and Group IV (■) received 5 × 105 tumor cells and 1 × 106 tumor specific anti-LT391-06 CTLs. When the tumor volume reached ~500 mm3, mice were sacrificed and the tumors were excised for further histological studies. The graph shows means ± s.d. of tumor volume. B, C. HLA class I antigen expression in lung tumor cells grown subcutaneously with CTL B. Subcutaneously grown human lung tumor cells co-injected with influenza specific CTL clone or C. subcutaneously grown human lung tumor cells co-injected with tumor antigen specific CTL clone in mice. Tumor tissues were fixed in formalin and stained with HLA class I heavy chain-specific mAb HC-10. Original magnification: ×400